Short Structured Psychological Intervention for Adults With ADHD - a Randomized Controlled Trial
Primary Purpose
Attention Deficit Disorder With Hyperactivity
Status
Unknown status
Phase
Not Applicable
Locations
Sweden
Study Type
Interventional
Intervention
Short ADHD Intervention
Self-help material with limited therapist support
Sponsored by
About this trial
This is an interventional treatment trial for Attention Deficit Disorder With Hyperactivity focused on measuring ADHD, Attention Deficit, Psychological Intervention, CBT, DBT, Self-Help, Adherence, Short Intervention
Eligibility Criteria
Inclusion Criteria:
- Swedish citizen
- Clinical Diagnosis of ADHD according to DSM-IV or DSM-5.
- Score of 17 or higher on the Adult ADHD Self Report Scale (ASRS v1.1), on any one of the two subscales.
- Not medically treated for ADHD symptoms throughout the study period, or medically treated with central stimulants or comparable substances since at least one month, with no significant changes in dosage and no anticipated significant changes in dosage.
- No change in any other medical treatment for psychiatric symptoms.
- Ability to participate in treatment during the study period.
- Abstinence from illegal substance use for at least three months.
- Access to and ability to use Internet and mobile phone during the study period.
- Ability to understand Swedish in speech and writing, and ability to fill-out forms online.
Exclusion Criteria:
- Clinical diagnosis of substance use disorder within three months prior to screening. Earlier episodic use of illegal substances is not excluding.
- Co-existing psychiatric condition or disorder expected to render the participant unable to follow-through the study processes.
- IQ ≤85 according to a prior neuropsychological assessment.
- Suicidality assessed at the first assessment interview.
- Organic brain syndrome.
- Autism spectrum disorder (ASD) where function is deemed too low for the treatment to be carried out, defined as ASD level 2 and level 3 according to DSM-5 and/or ASD with accompanying intellectual impairment and/or accompanying language impairment.
- Severe depression, defined as >34 on the MADRS-S or at a clinical assessment.
- Other current psychological treatment for ADHD or prior participation in treatment deemed to interfere with the study design.
- Limited or very limited self-rated recognition of problems regarding impulse control and/or emotional instability, in combination with low self-rated impairment, on a tailor-made measure.
Sites / Locations
- Cereb ABRecruiting
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Active Comparator
Arm Label
SAINT
Self-help material
Arm Description
Outcomes
Primary Outcome Measures
Change (from baseline) on The Adult ADHD Quality of Life Questionnaire (AAQoL)
Secondary Outcome Measures
Change (from baseline) on ADHD Self-Report Scale (ASRS; Self-report)
Change (from baseline) on the ADHD Rating Scale (ADHD RS; Assessed by an expert rater)
Change (from baseline) on Montgomery Åsberg Depression Rating Scale (MADRS-S; Self-report)
Change (from baseline) on Sheehan Disability Scale (SDS; Self-report)
Change (from baseline) on Difficulties in Emotion Regulation Scale (Brief Version; DERS-16; Self-report)
Change (from baseline) on Satisfaction With Life Scale (SWLS; Self-report)
Change (from baseline) on Perceived Stress Scale (PSS; Self-report)
Change (from baseline) on Clinical Global Impression - Severity Scale (CGI-S; Assessed by an expert rater)
Full Information
NCT ID
NCT04439422
First Posted
June 17, 2020
Last Updated
October 11, 2020
Sponsor
Cereb AB
Collaborators
Karolinska Institutet
1. Study Identification
Unique Protocol Identification Number
NCT04439422
Brief Title
Short Structured Psychological Intervention for Adults With ADHD - a Randomized Controlled Trial
Official Title
Short Structured Psychological Intervention for Adults With ADHD - a Randomized Controlled Trial
Study Type
Interventional
2. Study Status
Record Verification Date
October 2020
Overall Recruitment Status
Unknown status
Study Start Date
August 25, 2020 (Actual)
Primary Completion Date
August 2021 (Anticipated)
Study Completion Date
August 2022 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Cereb AB
Collaborators
Karolinska Institutet
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
5. Study Description
Brief Summary
The purpose of this study is to evaluate the effects of a novel psychological intervention for adult ADHD through a randomized controlled trial. Participants will be randomized to receive either a face-to-face manualized short psychological intervention, SAINT, or corresponding self-help material with limited access to therapist support. The main objective is to evaluate whether SAINT will show better outcomes on measures of ADHD-related symptoms, everyday function, and quality-of-life measures, when compared to the self-help material, and if any possible differences in outcomes are related to better treatment adherence in SAINT.
Detailed Description
ADHD is associated with deficiencies in short-term memory and executive function, negatively affecting patients' abilities to organize, schedule, multitask, follow through on instructions and finish jobs. This leads to uneven performance and possibly chronic underperformance in relation to actual intellectual resources. Psychiatric comorbidity is common for patients with ADHD, with 70-80% of adult patients meeting the criteria for at least one more clinical diagnosis. ADHD is also associated with sensation seeking and reckless behavior, including substance use and criminal activity.
Despite an increase in demand for assessment and treatment of ADHD among adults, access to evidence-based treatment is limited. In Sweden, most adult patients with ADHD are only offered pharmacological treatment. Pharmacological treatment, while in many cases effective, does not meet the demands of all patients, with 20-50% of patients not experiencing enough initial effect and/or excessive side-effects. Pharmacological treatment of ADHD also shows problems with long-term adherence, with approximately half of patients terminating treatment within the first two years, regardless of initial effect. Research on psychological treatment for adult ADHD is limited, though studies on behavioral treatment, including short-term therapies based on cognitive behavior therapy (CBT) and dialectic behavior therapy (DBT), have shown promising results.
This project, dubbed Short ADHD Intervention (SAINT), is based on previous research and pilot-studies of psychological treatments for adult ADHD. An existing treatment manual, based on CBT and DBT practices, will be fitted into a five-session, intensive face-to-face behavioral intervention, with a booster session at a one-month follow-up. The intervention will be compared to an equally long, active comparative control, consisting of self-help material and limited therapist support via Internet. Approximately 80 participants will be recruited at outpatient clinics in Stockholm. The participants will be randomized to receive either SAINT or the self-help material and limited therapist support.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Attention Deficit Disorder With Hyperactivity
Keywords
ADHD, Attention Deficit, Psychological Intervention, CBT, DBT, Self-Help, Adherence, Short Intervention
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
Outcomes Assessor
Allocation
Randomized
Enrollment
80 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
SAINT
Arm Type
Experimental
Arm Title
Self-help material
Arm Type
Active Comparator
Intervention Type
Behavioral
Intervention Name(s)
Short ADHD Intervention
Other Intervention Name(s)
SAINT
Intervention Description
Short, intensive psychological intervention based on CBT and DBT practices
Intervention Type
Other
Intervention Name(s)
Self-help material with limited therapist support
Intervention Description
Self-help material from an evidence-based treatment manual for adult ADHD with access to limited therapist support via Internet (control group)
Primary Outcome Measure Information:
Title
Change (from baseline) on The Adult ADHD Quality of Life Questionnaire (AAQoL)
Time Frame
Baseline, 5 weeks (post treatment), 9 weeks (FU1) 17 weeks (FU3)
Secondary Outcome Measure Information:
Title
Change (from baseline) on ADHD Self-Report Scale (ASRS; Self-report)
Time Frame
Baseline, 5 weeks (post treatment), 9 weeks (FU1) 17 weeks (FU3)
Title
Change (from baseline) on the ADHD Rating Scale (ADHD RS; Assessed by an expert rater)
Time Frame
Baseline, 5 weeks (post treatment)
Title
Change (from baseline) on Montgomery Åsberg Depression Rating Scale (MADRS-S; Self-report)
Time Frame
Baseline, 5 weeks (post treatment), 9 weeks (FU1) 17 weeks (FU3)
Title
Change (from baseline) on Sheehan Disability Scale (SDS; Self-report)
Time Frame
Baseline, 5 weeks (post treatment), 9 weeks (FU1) 17 weeks (FU3)
Title
Change (from baseline) on Difficulties in Emotion Regulation Scale (Brief Version; DERS-16; Self-report)
Time Frame
Baseline, 5 weeks (post treatment), 9 weeks (FU1) 17 weeks (FU3)
Title
Change (from baseline) on Satisfaction With Life Scale (SWLS; Self-report)
Time Frame
Baseline, 5 weeks (post treatment), 9 weeks (FU1) 17 weeks (FU3)
Title
Change (from baseline) on Perceived Stress Scale (PSS; Self-report)
Time Frame
Baseline, 5 weeks (post treatment), 9 weeks (FU1) 17 weeks (FU3)
Title
Change (from baseline) on Clinical Global Impression - Severity Scale (CGI-S; Assessed by an expert rater)
Time Frame
Baseline, 5 weeks (post treatment)
Other Pre-specified Outcome Measures:
Title
Clinical Global Impression - Improvement Scale (CGI-I; Assessed by an expert rater)
Time Frame
5 weeks (post treatment)
Title
Client Satisfaction Questionnaire (CSQ-8; Self-report)
Time Frame
5 weeks (post treatment)
Title
Treatment Credibility Scale (TCS; Self-report)
Time Frame
1 week, 3 weeks
Title
Treatment Evaluation (Self-report)
Description
A tailor-made formulary to evaluate the participants' experience of the interventions, including any possible difficulties.
Time Frame
5 weeks (post treatment)
Title
Adherence to Treatment (Self-report)
Description
Using a tailor-made formulary.
Time Frame
1 week, 2 weeks, 3 weeks, 4 weeks, 5 weeks (post treatment),9 weeks (FU1) 17 weeks (FU3)
Title
Session Attendance (Assessed by an expert rater)
Description
SAINT arm only.
Time Frame
1 week, 2 weeks, 3 weeks, 4 weeks, 5 weeks (post treatment), 9 weeks (FU1)
Title
Adverse Events During Treatment (Self-report)
Description
Using a tailor-made formulary.
Time Frame
5 weeks (post treatment), 9 weeks (FU1) 17 weeks (FU3)
Title
Changes in Other Treatment(s) During the Study Period (Self-report)
Description
Using a tailor-made formulary.
Time Frame
5 weeks (post treatment),9 weeks (FU1) 17 weeks (FU3)
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Swedish citizen
Clinical Diagnosis of ADHD according to DSM-IV or DSM-5.
Score of 17 or higher on the Adult ADHD Self Report Scale (ASRS v1.1), on any one of the two subscales.
Not medically treated for ADHD symptoms throughout the study period, or medically treated with central stimulants or comparable substances since at least one month, with no significant changes in dosage and no anticipated significant changes in dosage.
No change in any other medical treatment for psychiatric symptoms.
Ability to participate in treatment during the study period.
Abstinence from illegal substance use for at least three months.
Access to and ability to use Internet and mobile phone during the study period.
Ability to understand Swedish in speech and writing, and ability to fill-out forms online.
Exclusion Criteria:
Clinical diagnosis of substance use disorder within three months prior to screening. Earlier episodic use of illegal substances is not excluding.
Co-existing psychiatric condition or disorder expected to render the participant unable to follow-through the study processes.
IQ ≤85 according to a prior neuropsychological assessment.
Suicidality assessed at the first assessment interview.
Organic brain syndrome.
Autism spectrum disorder (ASD) where function is deemed too low for the treatment to be carried out, defined as ASD level 2 and level 3 according to DSM-5 and/or ASD with accompanying intellectual impairment and/or accompanying language impairment.
Severe depression, defined as >34 on the MADRS-S or at a clinical assessment.
Other current psychological treatment for ADHD or prior participation in treatment deemed to interfere with the study design.
Limited or very limited self-rated recognition of problems regarding impulse control and/or emotional instability, in combination with low self-rated impairment, on a tailor-made measure.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Berkeh Nasri, PhD
Phone
+46739328138
Email
berkeh.nasri@cereb.se
Facility Information:
Facility Name
Cereb AB
City
Stockholm
Country
Sweden
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Berkeh Nasri, PhD
12. IPD Sharing Statement
Learn more about this trial
Short Structured Psychological Intervention for Adults With ADHD - a Randomized Controlled Trial
We'll reach out to this number within 24 hrs